RT @_Castillo_Pedro: Glucocorticoids (GC) in SLE on Belimumab ð¹Post-hoc, 5 phase 3 trials ð¹1° endpoint >25% pr
Tweet Content
Glucocorticoids (GC) in SLE on Belimumab
🔹Post-hoc, 5 phase 3 trials
🔹1° endpoint >25% pred↘️ to <7.5mg/d
🔹BEL n=1869; Placebo n=1217
🔹Baseline: 88% on GC; mean ~12.3mg/d pred
🔹Endpoint met by 17% BEL and 12% Pbo (p=0.0024)
https://t.co/xp9LamlpHZ
#ACR21 Abst#1283 @RheumNow
Links
Reduction in Glucocorticoid Use in Patients with Systemic Lupus Erythematosus T…
https://bit.ly/3mY73Ls
Show on Archive Page
On
Display in Search Results
On
PDQ
Off